Does PSA Testing Influence the Natural History of Prostate Cancer? John Anderson  European Urology Supplements  Volume 1, Issue 5, Pages 3-10 (August 2002) DOI: 10.1016/S1569-9056(02)00047-7

Fig. 1 Disease-specific mortality by tumour grade in a cohort of 451 men aged 65–75 years at diagnosis and managed conservatively [10] (reproduced with permission). European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00047-7)

Fig. 2 Trial profile of the Quebec Prostate Cancer Screening Program (man-years [m-y]) [21] (reproduced with permission). European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00047-7)

Fig. 3 Proportion of men in the ERSPC and PLCO studies with a screening indication for biopsy [23] (reproduced with permission). European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00047-7)

Fig. 4 Age-adjusted rates of prostate cancer: (a) incidence, and (b) mortality in the SEER Program, 1973–1996. The shaded areas on the figures represent the period following the introduction of PSA testing [24] (reproduced with permission). European Urology Supplements 2002 1, 3-10DOI: (10.1016/S1569-9056(02)00047-7)